KSKathleen A. Stringer

Kathleen A. Stringer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kathleen A. Stringer has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Emerging Role of Anticoagulants and Fibrinolytics in the Treatment of Acute Respiratory Distress Syndrome

    by Robert MacLaren, Kathleen A. Stringer

    Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are associated with high mortality rates despite therapeutic advances. The pathogenesis of ALI and ARDS is similar to that of sepsis, as these disease states involve uncontrolled host defense responses that lead to inflammation, endothelial damage, enhanced coagulation, diminished fibrinolysis, and fibroproliferation. Recent studies of anticoagulants have shown positive outcomes in patients with severe sepsis. In addition, emerging evidence suggests that the use of anticoagulants, such as tissue factor pathway inhibitor, antithrombin, thrombomodulin, heparin, activated protein C, and fibrinolytics (plasminogen activators and particularly tissue plasminogen activator), may be useful in the treatment of ALI and ARDS. Data from experimental models of sepsis, ALI, and ARDS indicate that some of these agents improve lung function and oxygenation. Although clinical data are less convincing than these findings, results from clinical trials may influence the design of future studies.


  • Feasibility of Tissue Plasminogen Activator Formulated for Pulmonary Delivery

    by John S. Dunn, Rajiv Nayar, Jackie Campos, Brooks M. Hybertson, Yue Zhou, Mark Cornell Manning, John E. Repine, Kathleen A. Stringer

    This study was conducted to assess the feasibility of a pulmonary formulation of tissue plasminogen activator (tPA) for nebulization into the airway by measuring protein stability, biologic activity, particle size, and estimating human lung distribution.


  • Particulate phase cigarette smoke increases MnSOD, NQO1, and CINC-1 in rat lungs

    by Kathleen A. Stringer, Brian M. Freed, John S. Dunn, Scott Sayers, Daniel L. Gustafson, Sonia C. Flores


  • ADMINISTRATION OF EXOGENOUS TISSUE PLASMINOGEN ACTIVATOR REDUCES OEDEMA IN MICE LACKING THE TISSUE PLASMINOGEN ACTIVATOR GENE

    by Kathleen A Stringer, John S Dunn, Daniel L Gustafson

    Summary: 1. It has recently become apparent that tissue plasminogen activator (tPA) modulates inflammation in diseases such as rheumatoid arthritis (RA) and acute respiratory distress syndrome (ARDS).2. We have shown previously that tPA has anti‐inflammatory activity in in vivo models of oedema or inflammation.3. The present study investigated the ability of exogenous recombinant tPA (rtPA) to reduce carrageenan‐mediated oedema in mice lacking the tPA gene, testing the hypothesis that rtPA treatment may be beneficial in diseases such as RA and ARDS in which there is a paucity of endogenous tPA.4. Knockout mice deficient in the tPA gene and matching wild‐type mice received an intraplantar injection (25 µL) of carrageenan (1.5%, w/v) following either vehicle (sterile water for injection) or tPA (12 mg/kg).5. Footpad oedema was measured, an oedema index was calculated and tissue myeloperoxidase (MPO) activity was determined. Mean oedema indices were higher in untreated tPA (–/–) mice than untreated wild‐type mice. Pretreatment with rtPA in either tPA (–/–) or wild‐type mice reduced the mean measured peak footpad oedema index by 63 and 48%, respectively. Tissue MPO activity was not different between treatment groups.6. We conclude that exogenous rtPA has the ability to reduce acute oedema without altering neutrophil infiltration into the site of injury in both tPA (–/–) and wild‐type mice and that endogenous tPA may participate in the inflammatory process, as evidenced by higher oedema indices in untreated tPA (–/–) mice. These data provide support for the potential clinical utility of exogenous rtPA in the treatment of inflammatory diseases, such as RA and ARDS, in which there is a paucity of tPA.


  • Impact of a Critical Pathway on Acute Myocardial Infarction Quality Indicators

    by Megan B. Bestul, Marianne McCollum, Kathleen A. Stringer, Jeb Burchenal

    Study Objective. To determine the impact of a critical pathway on acute myocardial infarction (AMI) quality indicators.Design. Retrospective chart review.Setting. Large university hospital.Patients. One hundred seventy‐five patients who underwent primary percutaneous transluminal angioplasty for AMI (control group 89 patients, intervention group 86 patients).Measurements and Main Results. The medical records of the control group (1998–1999) were reviewed for door‐to‐balloon (DtB) time (the time between the patient's arrival at the emergency department and the first balloon inflation during a percutaneous transluminal coronary angioplasty procedure). Drug therapy prescribed at hospital discharge (aspirin, β‐blocker, angiotensin‐converting enzyme [ACE] inhibitor, and lipid‐lowering therapy) was also reviewed. The data collected for the control group were compared with the intervention group data (2000–2001). The impact of the pathway was evaluated using the Wilcoxon rank sum test, odds ratios (ORs), and χ2 tests. The DtB time was significantly lower in the intervention group versus the control group (91.5 vs 108 min, pConclusion. These data suggest that in the current era of published treatment guidelines, implementation of a critical pathway can further improve AMI quality indicators and clinical care.


  • An Institution‐Specific Heparin Titration Nomogram: Development, Validation, and Assessment of Compliance

    by Deb S. Sherman, Susan H. Clarke, Jerry B. Lefkowitz, Robert J. Valuck, JoAnn Lindenfeld, Kathleen A. Stringer

    Study Objective. To develop, validate, and assess compliance with a heparin titration nomogram.Design. Prospective, open‐label trial.Setting. University teaching hospital.Subjects. Patients admitted with heart failure who required therapy with intravenous unfractionated heparin.Intervention. An in vitro concentration‐response was determined by measuring activated partial thromboplastin times (aPTTs) on normal pooled plasma containing known concentrations of heparin. The therapeutic aPTT range was determined from the concentration‐response by using the therapeutic heparin concentration range of 0.2–0.4 U/ml (protamine neutralization). Patients were consecutively enrolled, and therapy was managed by using the heparin titration nomogram. Paired aPTT‐heparin concentrations were obtained, and nomogram validation was performed by comparing the in vitro and the ex vivo concentration‐responses with use of linear regression. Nomogram compliance also was assessed.Measurements and Main Results. The therapeutic aPTT ranges based on in vitro and ex vivo data were determined to be 45–72 seconds and 47–61 seconds, respectively. The ranges were significantly different (pConclusion. These results confirm that, even in a relatively homogeneous disease‐state patient population, in vitro data do not accurately predict ex vivo data. If in vitro data are used to develop an institution‐specific nomogram, a validation procedure should be used to ensure accuracy. Although 100% compliance to a nomogram may not be attainable, it should be expected. Therefore, a compliance rate of 88% is concerning and suggests a need for increased nursing and physician education.


  • Open Access

    The Evolving Role of Platelet Glycoprotein IIb/IIIa Inhibitors in the Management of Acute Coronary Syndromes

    by Kathleen A Stringer

    OBJECTIVE: To briefly discuss the pathophysiology of acute coronary syndromes (ACS) and to present the clinical data currently available regarding the use of platelet glycoprotein (GP) IIb/IIIa inhibitors in the management of ACS. DATA SOURCES: Literature on antithrombotic therapy in ACS was identified using a MEDLINE search (January 1988–September 1998), along with the Agency on Health Care Policy and Research guidelines for the management of unstable angina. Abstracts from recent scientific meetings were also reviewed. STUDY SELECTION: Review articles from the cardiology literature (pathophysiology) and randomized, controlled clinical trials of currently approved platelet GP IIb/IIIa inhibitors in ACS were evaluated. Ex vivo platelet aggregation studies and pharmacology literature were also included. Abstract data were included to illustrate specific points when published literature was not available. DATA EXTRACTION: Study data were evaluated based on study design, outcome parameters, and adverse drug reactions. Clinical information from review articles was evaluated based on applicability to the treatment of ACS. DATA SYNTHESIS: Platelet adhesion and aggregation are pivotal events in the pathophysiology of ACS. The GP IIb/IIIa inhibitors represent a new and unique class of drugs that block fibrinogen and von Willebrand factor–mediated platelet aggregation, the common end point of all biologic pathways of platelet aggregation. Three agents are currently approved by the Food and Drug Administration: abciximab, a monoclonal antibody; eptifibatide, a synthetic peptide; and tirofiban, a synthetic nonpeptide. CONCLUSIONS: Clinical trial data demonstrate efficacy of all three GP IIb/IIIa inhibitors in reducing the combined end point of morbidity and mortality in patients undergoing angioplasty. Eptifibatide and tirofiban also reduce the combined end point of morbidity and mortality in patients with unstable angina. These data expand the present role of platelet GP IIb/IIIa inhibitors by providing evidence for their effectiveness in the medical treatment of ACS. However, the specific role that these agents will have in the management of ACS is yet to be fully defined.


  • Tissue Plasminogen Activator (tPA) Inhibits Interleukin-1 Induced Acute Lung Leak

    by Kathleen A Stringer, Brooks M Hybertson, Okyong J Cho, Zoe Cohen, John E Repine


  • Clinical trials in thrombolytic therapy, Part 1: Outcome markers that go beyond mortality reduction

    by Kathleen A. Stringer

    The use of outcome markers other than mortality reduction alone for evaluating thrombolytic agents in patients with acute myocardial infarction (AMI) is discussed. Mortality has been a primary endpoint in clinical trials evaluating thrombolytic agents for treatment of AMI. However, differences in mortality rates among thrombolytics are 1% or less and require tens of thousands of patients to detect. Broadening the endpoints studied will allow for more extensive data collection and more comprehensive cost-effectiveness analysis, enabling clinicians to make better decisions. The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-1) trial measured not only mortality but issues related to the patency of the infarct-related artery and complications. Other potentially important outcome markers after AMI are left ventricular function; markers of reperfusion, such as early resolution of ST-segment elevation; and resolution of chest pain. Available long-term data show that the mortality benefit from alteplase is sustained over time and is correlated with enzymatically determined infarct size, left ventricular function, the number of diseased vessels, and Thrombolysis in Myocardial Infarction flow grade at the time of discharge from the hospital. Clinicians must also consider risk factors for stroke. Outcome measures other than mortality alone may help in determining which thrombolytic agent is most effective clinically and in financial decision-making without requiring large, expensive trials.